A report from Deutsche Bank reiterates its Buy rating and $67 price target on Regeneron Pharmaceuticals REGN.
In the report, Deutsche Bank writes, “Efficacy data from recently unblinded HARBOR study did not support initiation of further high dose clinical studies and the company will be discussing 0.5mg PRN (as needed) dosing with the regulators. In our opinion, this indicates that 0.5 mg is the optimal dose of Lucentis and increasing the dose does not improve vision in wet-AMD patients."
REGN closed yesterday at $63.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in